lilly_andrew_hotchkiss

Lilly promotes Andrew Hotchkiss

pharmafile | June 9, 2011 | Appointment | Research and Development, Sales and Marketing appointment, research and development, sales and marketing 

Lilly has appointed Andrew Hotchkiss president of its operations in Australia, Canada and Europe.

Andrew has been with the company for 25 years and was most recently working as VP and international business unit leader for Lilly Oncology.

His roles with the company include serving as general manager of both Italy and the UK and in his new position Andrew will be based in the UK at Lilly’s Research Centre at Erl Wood in Surrey.

Advertisement

Andrew said: “As an innovation-focused company we have a well-established portfolio of important medicines to help patients, and we have a future pipeline that will help continue our long tradition in making groundbreaking advances.

“I am proud and excited to have the opportunity to lead Lilly’s hugely talented pool of dedicated employees across the region, who are focused on the mission to help improve outcomes for patients.”

The company said Andrew would build on the successes of its outgoing president Karim Bitar, who steps down on 17 June, and spearhead Lilly’s activities across the ACE region.

Bryce Carmine, executive VP and president of Lilly Bio-Medicines, said: “Andrew is a dynamic leader with more than 25 years of experience across various sectors of our business.

“He will be a tremendous asset to the organisation in leading our efforts to maximise the value of our marketed products and prepare Lilly’s ACE region for the next wave of innovative Lilly medicines.”

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content